Sidley represented OMERS Life Sciences in the US$650 million strategic financing of Verona Pharma plc (NASDAQ: VRNA), together with funds managed by Oaktree Capital Management, L.P., consisting of up to US$400 million in term loans and up to US$250 million in funding from the sale of a redeemable capped interest in future ensifentrine-related revenue. The team was led by Asher M. Rubin, Adriana V. Tibbitts (Technology and Life Sciences Transactions), and Angela Fontana (Global Finance); and included Collin J. Marshall (Technology and Life Sciences Transactions); Cynthia Bai, Sean Damm, Mimi Mallory, and Henry Sasse (Global Finance); William E. Curtin, Sam Newman, and Juliana Hoffman (Restructuring); Tara M. Lancaster and Andy J. Lau (Tax); Robert Mandell (Capital Markets); and Michael D. Mann (White Collar: Government Litigation and Investigations). For additional information, please refer to the press release.~~Sidley represented OMERS Life Sciences in the US$650 million strategic financing of Verona Pharma plc (NASDAQ: VRNA), together with funds managed by Oaktree Capital Management, L.P., consisting of up to US$400 million in term loans and up to US$250 million in funding from the sale of a redeemable capped interest in future ensifentrine-related revenue. The team was led by Asher M. Rubin, Adriana V. Tibbitts (Technology and Life Sciences Transactions), and Angela Fontana (Global Finance); and included Collin J. Marshall (Technology and Life Sciences Transactions); Cynthia Bai, Sean Damm, Mimi Mallory, and Henry Sasse (Global Finance); William E. Curtin, Sam Newman, and Juliana Hoffman (Restructuring); Tara M. Lancaster and Andy J. Lau (Tax); Robert Mandell (Capital Markets); and Michael D. Mann (White Collar: Government Litigation and Investigations). For additional information, please refer to the press release.